BNS vs CM

The Bank of Nova Scotia (BNS) exhibits a weak financial health profile with a Piotroski F-Score of 2/9, signaling significant concerns in profitability, leverage, and operating efficiency. Despite this, the stock shows strong recent earnings growth (YoY EPS +58.2%) and a robust dividend yield of 4.28%, supported by a high but sustainable payout ratio. Valuation metrics suggest the stock is trading slightly above analyst targets ($74.87 vs. $70.40) and above the Graham Number of $68.74, though below the growth-based intrinsic value of $121.54. Technical indicators are bearish (10/100), and insider sentiment is neutral, reflecting limited conviction despite solid dividend strength.

The deterministic health profile is concerning, highlighted by a weak Piotroski F-Score of 2/9, indicating significant deterioration in fundamental financial strength. While the company exhibits explosive growth (Earnings +46.6% YoY) and a strong track record of earnings beats, these are countered by a severely bearish technical trend (10/100) and a current price that has already exceeded analyst target prices. The stock trades at a premium to its Graham Number ($89.37) but remains well below its growth-based intrinsic value ($207.09), suggesting a conflict between short-term health risks and long-term growth potential.